News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phosphate Therapeutics Appoints Dr Sandy Eisen to Its Board as a Non-Executive Director


6/3/2013 9:40:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

London, UK, 3rd June 2013. Phosphate Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces the recent appointment of Dr Sandy Eisen to its Board as a Non-Executive Director, effective from May 2013. With principal funding from its investment partner Inventages, Phosphate Therapeutics is currently progressing PT20 - a novel phosphate binder to treat hyperphosphataemia associated with end-stage renal disease - towards pivotal clinical trials through an exclusive agreement with Shield Therapeutics. PT20 was licensed from MRC Technology in 2012.

Dr Eisen has 24 years of pharmaceutical regulation and commercial pharmaceutical medicine experience, having worked in several senior government positions as an EU and UK regulator and from 2006 – 2011 working as the Chief Medical Officer for Teva Pharmaceuticals Europe. He brings a deep knowledge of regulatory requirements and drug development issues to the Board of Phosphate Therapeutics.

Dr Eisen graduated from Cambridge University as a physician after studying clinical medicine at St Bartholomew’s Hospital Medical School in London. He also holds a BA and MBA from Cambridge as well as postgraduate medical qualifications in both Surgery (FRCS England) and Pharmaceutical Medicine (Diploma in Pharmaceutical Medicine, RCP/FPM London).

Commenting on the appointment Carl Sterritt, Chief Executive Officer of Phosphate Therapeutics, said: “I am delighted to see Sandy joining the Board of Phosphate Therapeutics. I am sure his wealth of experience in new drug and new biological applications, clinical trials and drug safety will prove most valuable to the ongoing development of PT20, our lead asset.”

Newly-appointed Board Director Dr Eisen, commented:

“PT20 has shown significant therapeutic promise in early studies and has received considerable backing to complete Phase 2 development. I look forward to working with this experienced team as we work towards bringing PT20 to the market in the shortest possible time.”

For more information about Phosphate Therapeutics, please contact:

M:Communications

Mary-Jane Elliott / Hollie Vile

Tel +44 (0)20 7920 2330

E-mail: healthcare@mcomgroup.com

About Phosphate Therapeutics

Phosphate Therapeutics is a UK-based specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals such as PT20. The company is developing PT20 through an exclusive agreement with Shield Therapeutics (www.shieldtherapeutics.com). For more information please see www.phosphatetx.com.

About MRC Technology

MRC Technology (www.mrctechnology.org) is the technology transfer company of the Medical Research Council and is responsible for adding commercial value to cutting edge scientific discoveries through strategic patent protection, creative licensing of intellectual property (IP), partnered research or further scientific development. MRC Technology also has small molecule drug discovery and therapeutic antibody facilities, providing lead stage therapeutic assets to pharmaceutical and biotechnology companies.

About Inventages

Inventages is one of the world’s biggest specialised life science venture capital investors with US$1.5 billion committed capital. It invests globally in healthcare, medical nutrition and consumer health. Beyond capital infusion and board participation, Inventages strives to contribute to the growth of the management teams and companies in which it invests by leveraging its experience, together with extensive networks and relationships. For further information, please visit www.inventages.com.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES